Show simple item record

dc.contributor.authorMunir, K.M.
dc.contributor.authorLamos, E.M.
dc.date.accessioned2019-07-15T16:12:15Z
dc.date.available2019-07-15T16:12:15Z
dc.date.issued2017
dc.identifier.urihttps://www.scopus.com/inward/record.uri?eid=2-s2.0-85018329702&doi=10.1080%2f14656566.2017.1323878&partnerID=40&md5=fcaf11a4f015d05842d325ad9e9d2f95
dc.identifier.urihttp://hdl.handle.net/10713/9965
dc.description.urihttps://www.doi.org/10.1080/14656566.2017.1323878en_US
dc.language.isoen_USen_US
dc.publisherTaylor and Francis Ltden_US
dc.relation.ispartofExpert Opinion on Pharmacotherapy
dc.subjectAlogliptinen_US
dc.subjectdipeptidyl peptidase ?4 inhibitoren_US
dc.subjectlinagliptinen_US
dc.subjectsaxagliptinen_US
dc.subjectsitagliptinen_US
dc.titleDiabetes type 2 management: what are the differences between DPP-4 inhibitors and how do you choose?en_US
dc.typeArticleen_US
dc.identifier.doi10.1080/14656566.2017.1323878
dc.identifier.pmid28449622


This item appears in the following Collection(s)

Show simple item record